| Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies FT Cordingley, AV Hoffbrand, HE Heslop, M Turner, A Bianchi, JE Reittie, ... The Lancet 331 (8592), 969-971, 1988 | 368 | 1988 |
| Presence of HIV-1 Gag-specific IFN-γ+ IL-2+ and CD28+ IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection MJ Boaz, A Waters, S Murad, PJ Easterbrook, A Vyakarnam The Journal of Immunology 169 (11), 6376-6385, 2002 | 302 | 2002 |
| Tumour necrosis factors (α, β) induced by HIV-1 in peripheral blood mononuclear cells potentiate virus replication A Vyakarnam, J McKeating, A Meager, PC Beverley Aids 4 (1), 21-28, 1990 | 166 | 1990 |
| Novel innate immune functions of the whey acidic protein family CD Bingle, A Vyakarnam Trends in immunology 29 (9), 444-453, 2008 | 141 | 2008 |
| Raising antibodies by coupling peptides to PPD and immunizing BCG‐sensitized animals PJ Lachmann, L Strangeways, A Vyakarnam, G Evan Ciba Foundation Symposium 119‐Synthetic Peptides as Antigens: Synthetic …, 2007 | 103 | 2007 |
| HIV-1 infection of human CD4+ T cells in vitro. Differential induction of apoptosis in these cells. SJ Martin, PM Matear, A Vyakarnam Journal of immunology (Baltimore, Md.: 1950) 152 (1), 330-342, 1994 | 101 | 1994 |
| Altered production of tumour necrosis factors alpha and beta and interferon gamma by HIV‐infected individuals A Vyakarnam, P Matear, A Meager, G Kelly, B Stanley, I Weller, ... Clinical & Experimental Immunology 84 (1), 109-115, 1991 | 86 | 1991 |
| The related cytokines interleukin-13 and interleukin-4 are distinguished by differential production and differential effects on T lymphocytes A Minty, S Asselin, A Bensus-san, D Shire, N Vita, A Vyakarnam, ... European cytokine network 8 (2), 203-13, 1997 | 84 | 1997 |
| Unbiased identification of blood-based biomarkers for pulmonary tuberculosis by modeling and mining molecular interaction networks A Sambarey, A Devaprasad, A Mohan, A Ahmed, S Nayak, ... EBioMedicine 15, 112-126, 2017 | 82 | 2017 |
| Comparison between HIV-and CMV-specific T cell responses in long-term HIV infected donors L Papagno, V Appay, J Sutton, T Rostron, GMA Gillespie, GS Ogg, A King, ... Clinical & Experimental Immunology 130 (3), 509-517, 2002 | 82 | 2002 |
| Immunization of human HIV-seronegative volunteers with recombinant p17/p24: Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses SJ Martin, A Vyakarnam, R Cheingsong-Popov, D Callow, KL Jones, ... Aids 7 (10), 1315-1324, 1993 | 81 | 1993 |
| Innate immunity against HIV: a priority target for HIV prevention research P Borrow, RJ Shattock, A Vyakarnam, EUROPRISE Working Group Retrovirology 7, 1-17, 2010 | 76 | 2010 |
| HIV infection alters the production of both type 1 and 2 cytokines but does not induce a polarized type 1 or 2 state A Fakoya, PM Matear, E Filley, GAW Rook, J Stanford, RJC Gilson, ... Aids 11 (12), 1445-1452, 1997 | 75 | 1997 |
| Epidemiological risk factors for hypersensitivity reactions to abacavir* PJ Easterbrook, A Waters, S Murad, N Ives, C Taylor, D King, ... HIV medicine 4 (4), 321-324, 2003 | 71 | 2003 |
| BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+ and IGRA–Indian adults S Rakshit, A Ahmed, V Adiga, BK Sundararaj, PN Sahoo, J Kenneth, ... JCI insight 4 (24), 2019 | 54 | 2019 |
| A century of BCG: Impact on tuberculosis control and beyond A Ahmed, S Rakshit, V Adiga, M Dias, P Dwarkanath, G D’Souza, ... Immunological reviews 301 (1), 98-121, 2021 | 48 | 2021 |
| Th1 cells specific for HIV-1 gag p24 are less efficient than Th0 cells in supporting HIV replication, and inhibit virus replication in Th0 cells. A Vyakarnam, PM Matear, SJ Martin, M Wagstaff Immunology 86 (1), 85, 1995 | 47 | 1995 |
| Increased sensitivity of CD4+ T-effector cells to CD4+ CD25+ Treg suppression compensates for reduced Treg number in asymptomatic HIV-1 infection G Thorborn, L Pomeroy, H Isohanni, M Perry, B Peters, A Vyakarnam PloS one 5 (2), e9254, 2010 | 45 | 2010 |
| HIV–TB co‐infection: mechanisms that drive reactivation of Mycobacterium tuberculosis in HIV infection A Ahmed, S Rakshit, A Vyakarnam Oral diseases 22, 53-60, 2016 | 40 | 2016 |
| The vaccine journey for COVID-19: a comprehensive systematic review of current clinical trials in humans. E Checcucci, F Piramide, A Pecoraro, D Amparore, R Campi, C Fiori, ... Panminerva medica 64 (1), 72-79, 2020 | 35 | 2020 |
